New Cyclic Lipopeptide Compounds for Efficiently Inhibiting Cellular Inflammation and Collagen-Induced Arthritis in...

Area of Science:

• Immunology
• Pharmacology
• Medicinal Chemistry

Background:

• Rheumatoid arthritis (RA) is a systemic autoimmune disease with inadequate response to current therapies.
• Daptomycin (DAP), a cyclic lipopeptide (CLP), previously showed suppressive activity against arthritis in mouse models.
• There is a need for novel therapeutic agents to effectively manage RA.

Purpose of the Study:

• To design and synthesize novel DAP-derived CLPs through structural modification.
• To evaluate the in vitro and in vivo anti-RA effects of these new compounds.
• To investigate the underlying mechanisms of action for the most effective CLP derivative.

Main Methods:

• Synthesis of five novel DAP-derived CLPs by optimizing the loop structure of DAP.
• In vitro and in vivo assessment of anti-RA activity.
• Pharmacokinetic and peptide stability studies.
• Analysis of inflammatory cytokine levels (IL-6, TNF-α, IL-1β) and key signaling pathways (NF-κB, MAPK).

Main Results:

• CLP-d2 exhibited superior anti-RA effects compared to DAP.
• CLP-d2 demonstrated improved pharmacokinetic parameters and enhanced peptide stability.
• CLP-d2 significantly reduced inflammatory factors and inhibited NF-κB and MAPK signaling.
• CLP-d2 effectively decreased joint swelling, bone erosion, and disease progression in vivo.

Conclusions:

• DAP-derived CLPs, particularly CLP-d2, represent promising therapeutic candidates for rheumatoid arthritis.
• CLP-d2's enhanced efficacy is attributed to improved stability and targeted inhibition of inflammatory pathways.
• These findings support the potential druggability of DAP-derived CLPs for RA treatment.